Failure of cancer vaccines: The significant limitations of this approach to immunotherapy

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2665-2676

  Bodey, Bela ^a,e   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Active specific immunotherapy; Adjuvant; Antigenic determinants; Biological response modifiers (BRMs); Cancer progression; Cytokines; Dendritic cells; Idiotype; Immunophenotype (IP); Lymphokines; Microevolution; Neoplastic cell dedifferentiation; Neoplastic transformation; Recombinant vaccines; Tumor associated antigens (TAAs)

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CANCER; CANCER IMMUNIZATION; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT FAILURE;

ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CANCER VACCINES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DENDRITIC CELLS; HEMOCYANIN; HUMANS; NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0033855629     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Pardoll DM: Cancer vaccines. Immunol Today 14: 310-316, 1993.
2. Sinkovics J, Horvath J, Szabo-Szabari M: Human cancer vaccines. Leukemia 8 Suppl 1: S194-S197, 1994.
3. Sinkovics JG, Horvath JC: Vaccination against human cancers (review). Int J Oncol 16: 81-96, 2000.
4. Gattoni-Celli S, Cole DJ: Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin Oncol 23: 754-758, 1996.
5. Urban JL, Schreiber H: Tumor antigens. Annu Rev Immunol 10: 617-644, 1992.
6. Lewis JJ, Houghton AN: Definition of tumor antigens suitable for vaccine construction. Semin Cancer Biol 6: 321-327, 1995.
7. Robbins PF, Kawakami Y: Human tumor antigens recognized by T cells. Curr Opin Immunol 8: 628-636, 1996.
8. Triozzi PL, Stevens VC: Human chorionic gonadotropin as a target for cancer vaccines. Oncol Rep 6: 7-17, 1999.
9. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF: Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81: 748-754, 1999.
10. Disis ML, Cheever MA: Oncogenic proteins as tumor antigens. Curr Opin Immunol 8: 637-642, 1996.
11. Abrams SI, Hand PH, Tsang KY, Schlom J: Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 23: 118-134, 1996.
12. Blachere NE, Srivastava PK: Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 6: 349-355, 1995.
13. MacLean GD, Reddish MA, Koganty RR, Longenecker BM: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 19; 59-68, 1996.
14. Ragupathi G: Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 43: 152-157, 1996.
15. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM: Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 22: 54-66, 1999.
16. Kieber-Emmons T, Luo P, Qiu J, Chang TY, O I, Blaszczyk-Thurin M, Steplewski Z: Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol 17: 660-665, 1999.
17. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI: Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA 96: 5710-5715, 1999.
18. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145: 61-89, 1995.